In vitro & in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction

被引:22
作者
Xiang, Xiang Yuan [1 ]
Guo, Liang [1 ]
Gong, Yan Chun [1 ]
Li, Zi Ling [1 ]
Li, Yu Ping [1 ]
Liu, Zhi Yong [2 ]
Zhou, Ming [2 ]
机构
[1] Jiangxi Sci & Technol Normal Univ, Sch Life Sci, Nanchang 330013, Peoples R China
[2] Med Lab Anim Ctr Jiangxi Prov, Nanchang 330006, Peoples R China
基金
中国国家自然科学基金;
关键词
Pluronics; Poly(lactic acid); Biotin; Nanoparticle; Targeted drug delivery; BLOCK-COPOLYMERS; TRIBLOCK COPOLYMERS; CONTROLLED-RELEASE; PEG-PLA; DRUG; DELIVERY; MICELLES; CELLS; KINETICS; CARRIERS;
D O I
10.1016/j.ejps.2012.04.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Biotinylated Pluronic F127/poly(lactic acid) block copolymers (B-F127-PLA) were successfully synthesized previously by our group. In the present study, the release behaviors of paclitaxel-loaded B-F127-PLA nanoparticles and their targeting properties to human ovarian carcinoma cells were investigated. Paclitaxel (pac) loaded in B-F127-PLA nanoparticles shows an initial burst release in the first 6 h and followed by a slow release. The in vitro targeting behaviors of B-F127-PLA nanoparticles against human ovarian cancer cells (OVCAR-3, SKOV-3) were investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MU) tests and fluorescence microscopy (FM) technique. Targeting was based on a three-step biotin-avidin targeting approach using biotinylated anti-CA125 antibody specific for the CA125 antigen that is highly expressed on OVCAR-3 cells but not expressed on SKOV-3 cells. MU results show that the anticancer effect of paclitaxel in B-F127-PLA nanoparticles over OVCAR-3 cells was stronger than that over SKOV-3 cells, indicating that B-F127-PLA nanoparticles were delivered more effectively to OVCAR-3 cells than to SKOV-3 cells. The targeting behaviors of B-F127-PLA nanoparticles were further confirmed by FM technique. The intracellular distribution of B-F127-PLA nanoparticles was also studied using a triple-labeling method. It was observed that B-F127-PLA nanoparticles are mainly localized within the cytoplasm of OVCAR-3 cells. The in vivo antitumor efficacy of pac-loaded B-F127-PLA nanoparticles by three-step method as measured by change in tumor volume of OVCAR-3 implanted in Balb/C nude mice was greater than that by one-step method. (c) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:537 / 544
页数:8
相关论文
共 37 条
[1]   Self-porating polymersomes of PEG-PLA and PEG-PCL: hydrolysis-triggered controlled release vesicles [J].
Ahmed, F ;
Discher, DE .
JOURNAL OF CONTROLLED RELEASE, 2004, 96 (01) :37-53
[2]   Stimuli responsive polymers for biomedical applications [J].
Alarcón, CDH ;
Pennadam, S ;
Alexander, C .
CHEMICAL SOCIETY REVIEWS, 2005, 34 (03) :276-285
[3]   Solid lipid nanoparticles for targeted brain drug delivery [J].
Blasi, Paolo ;
Glovagnoli, Stefano ;
Schoubben, Aurelie ;
Ricci, Maurizio ;
Rossi, Carlo .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (06) :454-477
[4]  
Cannizzaro SM, 1998, BIOTECHNOL BIOENG, V58, P529, DOI 10.1002/(SICI)1097-0290(19980605)58:5<529::AID-BIT9>3.0.CO
[5]  
2-F
[6]   In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy [J].
Dong, Yuancai ;
Feng, Si-Shen .
BIOMATERIALS, 2007, 28 (28) :4154-4160
[7]   Surface-engineered nanoparticles for multiple ligand coupling [J].
Gref, R ;
Couvreur, P ;
Barratt, G ;
Mysiakine, E .
BIOMATERIALS, 2003, 24 (24) :4529-4537
[8]   ABA and BAB type triblock copolymers of PEG and PLA: A comparative study of drug release properties and "stealth" particle characteristics [J].
He, Guosen ;
Ma, Lwin Lwin ;
Pan, Jie ;
Venkatraman, Subbu .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 334 (1-2) :48-55
[9]   ABA-triblock copolymers from biodegradable polyester A-blocks and hydrophilic poly(ethylene oxide) B-blocks as a candidate for in situ forming hydrogel delivery systems for proteins [J].
Kissel, T ;
Li, YX ;
Unger, F .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (01) :99-134
[10]  
Knox SJ, 2000, CLIN CANCER RES, V6, P406